

Urine as an emerging liquid biopsy for bladder cancer biomarkers

Arya Mehta, Danielle Pasmans, Stephanie Jordaens, Sanne Bruyninckx, Koen Beyers, Vanessa Vankerckhoven April 2021

INTRODUCTION

Bladder cancer (BC) is the sixth most prevalent cancer worldwide in both men and women, with incidence and mortality increasing year by year¹. BC can originate in the urothelial cells lining inside the organ or other parts of the urinary tract².




Image adapted from https://v

Figure 1: Urinary Tract

In general, most types begin as non-muscle invasive urothelial carcinoma of the urinary bladder (UCB), which are localized to a region and do not invade the muscular wall and can be treated effectively. However, recurrence rates are high, with progression to muscle invasion UCB seen in 15% of patients³.

Given the high rate of recurrence, regular follow-ups are necessary to monitor progression⁴. Guidelines from the European Association of Urology (EAU) and the American Urological Association (AUA) suggest a combination of cystoscopy, cytology and imaging for surveillance of patients with UCB⁵, procedures that can be invasive and expensive. This intensive follow-up program makes BC one of the most expensive cancers to monitor¹.

Consequently, finding novel diagnostic strategies, that are noninvasive as well as cost-effective, can improve the quality of life of patients with BC. This white paper focuses on urine as sample type in BC research and how urinary biomarkers can be used for initial detection and follow-up of the disease.

CURRENT DETECTION METHODS ARE INVASIVE AND/OR OFFER POOR SENSITIVITY

Urinary biomarkers can improve detection. Currently, two methods are commonly used to detect BC:

Cystoscopy is the gold standard method for BC diagnosis, and involves inserting a cystoscope to observe any abnormal changes in the bladder. While cystoscopy can offer sensitivity of up to 90%, it can miss detection of small tumors². Additionally, the procedure is invasive, can be highly uncomfortable for the patient¹ and requires the experience of a urologist or nurse⁵.

Urine cytology involves observing a urine sample under a microscope to check for abnormal cells. Together with cystoscopy, this test is used in the diagnosis and follow-up of BC patients. Benefits of urine cytology are that it is non-invasive, inexpensive and offers a specificity of up to 98% for high-grade tumor detection. However, urinary cytology has an overall low sensitivity (less than 40%), making it challenging to use as a diagnostic tool for BC suspicion². Additionally, voided urine cytology requires trained cytopathologists and can be subject to inter-observer variability⁵.

As cystoscopy and urine cytology may not always be practical or feasible and is a costly procedure to follow repeatedly, finding alternative ways to detect as well as monitor BC is actively being researched².

There is an increased interest in non-invasive urinary biomarkers for initial detection and follow-up of the disease⁵. Given the function of the bladder and its close proximity to the urinary tract, urine as a sample type is particularly exciting as it can contain a reliable source of cancer biomarkers⁶.

Biomarker detection in urine for BC is also attractive as it allows noninvasive collection, as well as offers the possibility of repeated sampling. Table 1 shows the range of commercially urinary biomarker tests and kits that are available for the detection of BC.

Test	FDA/CE	Starting material	Biomarker type	Sensitivity	Specificity
uCyt+	YY	Exfoliated cells	Antigens/ Metabolites	73%	66%
NMP22	YY	Exfoliated cells	Peptides	40%	99%
UroVysion	YY	Exfoliated cells	DNA	72%	83%
BTA stat / BTA Track	ΥY	Exfoliated cells	Proteins	70%	75%
CxBladder	NN	Exfoliated cells	mRNA	82%	85%
Xpert Detection	NY	Exfoliated cells	mRNA	76%	85%
Uromonitor	NY	Exfoliated cells	Tumor cell DNA	74%	93%

Table 1: Commercially available urine tests for bladder cancer detection

TYPES OF BIOMARKERS IN URINE

Current FDA-approved tests have poor sensitivity or specificity, especially for low-grade and early-stage BC tumors and recurrent diagnoses. Therefore, other urinary biomarkers for BC diagnostics are currently being investigated⁷.

Possible biomarker candidates for BC in urine include exfoliated bladder cancer cells (EBCCs), cell-free DNA (cfDNA) and exosomes8. Exosomes, which are a class of extracellular vesicles released by all cells, and containing DNA, RNA, and proteins, are particularly promising as they represent a fingerprint of the cell of origin^{7,9}. Recent advancements in OMICs technologies, including genomics, epigenomics, proteomics, transcriptomics, and metabolomics have also improved our understanding of the molecular landscape causing cancers¹⁰.



GENOMICS

Interdisciplinary field of biology focusing on the structure, function, evolution, mapping, and editing of genomes.



METABOLOMICS Study of chemical processes involving metabolites, the small molecule substrates, intermediates and products of cell metabolism.



EPIGENOMICS

Study of the complete set of epigenetic modifications on the genetic material of a cell, the epigenome.



TRANSCRIPTOMICS

Study of an organism's transcriptome, the sum of all its RNA transcripts.



PROTEOMICS Study of an organism's transcriptome, the sum of all its RNA transcripts.

Figure 2: Definitions of omics

Genomic biomarkers

One particularly interesting biomarker that has shown to be a game-changer for disease monitoring and early detection of recurrence in BC is telomerase reverse transcriptase (TERT) promotor mutations. These mutations are extremely specific to BC and are not present in inflammatory or urinary infections, which are current drawbacks with the current non-invasive assays. These biomarkers are currently being included in BC urine-based tests, Uromonitor, Uromonitor-V2, and UroSEEK1.



In low-grade non-muscle invasive bladder cancer (NMIBC) tumors, mutations in the fibroblast growth factor receptor 3 (FGFR3) oncogene are frequent. One study showed the sensitivity for detecting BC by the FGFR3 mutation was $58\%^{11}$. Alternatively, in high-grade NMIBC tumors, mutations in p53 genes, which can cause dysregulation of the RAS-MAPK (mitogen-activated protein kinase) pathway are seen more often. Mutations in these genes are a strong indicator for BC. Mutations in RAS (Rat sarcoma) oncogenes occur in 13% of all BC tumors, providing valuable urinary biomarker candidates⁷.

Epigenomic biomarkers

Epigenetic factors also play an important role in the development of BC and can be useful biomarkers for disease detection and monitoring. Several studies have revealed the role of DNA methylation and methylated genes in influencing gene expression, ultimately leading to the development and progression of BC. However, further validation of these markers is required.

DNA methylation is a biological process by which methyl groups are added to the DNA molecule. Methylation can change the activity of a DNA segment without changing the sequence



- Hypermethylation an increase in the epigenetic methylation of DNA
- Hypomethylation a decrease in the epigenetic methylation of DNA

EpiCheck, a urine-based assay that analyses 15 DNA methylation markers commonly altered in BC, is currently the only developed product that looks at these biomarkers¹.

Transcriptomic biomarkers

Several studies have shown the potential of miRNAs in the detection of BC. While some studies used a single and others a panel of up and/or downregulated miRNAs, all of them showed sensitivity ranging from 72% to 90% and specificity ranging from 82% to $90\%^1$.



Long non-coding RNAs (IncRNAs) are important regulators of genetic and epigenetic expression and can interact with miRNAs promoting or repressing its activity

A recent meta-analysis concluded IncRNAs in urine may serve as non-invasive diagnostic biomarkers for BC, but more work is needed in this space ¹².

Proteomic biomarkers

Several urinary protein biomarkers for BC have been identified. One study comparing 46 patients with BC and 40 healthy controls reported urinary calprotectin can detect the cancer type with 80% sensitivity at 92% specificity. The median calprotectin level was 10-fold higher in patients than healthy controls¹³.

Other studies reported similar findings with a higher abundance of proteins in urine samples of BC patients (p < 0.05) compared with matched controls 14 .

For example, urinary proteins, stathmin-1 (also known as oncoprotein-18) and CD147 (also known as basigin or EMMPRIN) have also shown potential in BC detection. In a group of 30 patients and 30 controls, stathmin-1 had a sensitivity and specificity of 90% and 87% respectively, while CD147 a 97% and 100% respectively. Additionally, increased levels of Reg-1 (lithostathine-1-alpha) were also found in urine of BC patients.

Urothelial bladder carcinoma 1 (BLCA-1) and urothelial bladder carcinoma 4 (BLCA-4) are nuclear matrix proteins (NMPs) which can be elevated early in the development of BC, thereby can be used to detect the cancer in its initial stages, even before the appearance of a visible tumor⁷.

Table 2 shows a list of possible urine protein biomarkers that have been investigated in BC detection⁷:

Calprotectin	Cytokeratins 8, 18, 19	APOC2	
Stathmin-1	Survivin	APOC3	
CD147	ProEGF	APOE	
Reg-1	SAA4	CCL18	
BLCA-1	APOA1	PAI-1	
BLCA-4	APOA2	CD44	
Hyaluronidase	APOB		

Table 2: Protein biomarkers investigated for bladder cancer detection

Metabolomic biomarkers

A number of urinary metabolites for BC have been identified. A study profiling urine metabolites found 12 differential metabolites that distinguished the disease from control groups with a sensitivity of 91.3% and specificity of 92.5%¹⁷.

Further, a recent study performed urine metabolic profiling on two subject cohorts with and without BC in three independent platforms. A set of candidate biomarkers for BC including palmitoyl sphingomyelin, lactate, gluconate, adenosine, 2-methylbutyrylglycine and guanidinoacetate were suggested¹⁸.

FUTURE PERSPECTIVES

Given the wide array of biomarkers, urine is a promising sample type that can change the way the disease is detected and monitored in the future. Urine sampling also offers several other benefits as it is easy, quick and non-invasive.

However, for effective clinical applications, standardization of preanalytical conditions for the handling of urine specimens is required. More work needs to be done to better understand if variables such as urine collection, urine fractions, use of protease inhibitors, storage, and shipping conditions can influence sample quality and/or have an impact on BC biomarker detection⁶.

Novosanis' Colli-Pee®, a urine collection device prefilled with preservative, allows for volumetric collection of different urine volumes, which can facilitate and standardize detection and stabilization of urinary biomarkers in cancer research.

References

- (1) Batista R. et al. Biomarkers for Bladder Cancer Diagnosis and Surveillance: A Comprehensive Review. Diagnostics (Basel). 2020 Jan 13;10(1):39. doi: 10.3390/diagnostics10010039. PMID: 31941070.
- (2) Taheri M. et al. Expression profile of microRNAs in bladder cancer and their application as biomarkers. Biomed Pharmacother. 2020 Nov;131:110703. doi:10.1016/j.biopha.2020.110703. PMID:32890965.
- (3) Kouba E. et al. Liquid biopsy in the clinical management of bladder cancer: current status and future developments. Expert Rev Mol Diagn. 2020 Feb;20(2):255-264. doi: 10.1080/14737159.2019.1680284. PMID: 31608720.
- (4) Chan KM. et al. Shedding Light on Bladder Cancer Diagnosis in Urine. Diagnostics (Basel). 2020 Jun 8;10(6):383. doi: 10.3390/diagnostics10060383.PMID: 32521780.
- (S) Lozano F. et al. Current status of genetic urinary biomarkers for surveillance of non-muscle invasive bladder cancer: a systematic review. BMC Urol. 2020 Jul 14;20(1):99. doi: 10.1186/s12894-020-00670-x. PMID: 32664878.
- (6) Oliveira MC. et al. Urinary Biomarkers in Bladder Cancer: Where Do We Stand and Potential Role of Extracellular Vesicles. Cancers (Basel). 2020 May 29;12(6):1400. doi: 10.3390/cancers12061400. PMID: 32485007.
- (7) Oeyen E. et al. Bladder Cancer Diagnosis and Follow-Up: The Current Status and Possible Role of Extracellular Vesicles. Int J Mol Sci. 2019 Feb 14;20(4):821. doi: 10.3390/ijms20040821. PMID: 30769831.
- (8) Chen Ck. et al. Urine biopsy technologies: Cancer and beyond. Theranostics. 2020 Jun 22;10(17):7872-7888. doi: 10.7150/thno.44634. PMID: 32685026.

 (9) Kalluri R. et al. The biology, function, and biomedical applications of exosomes. Science. 2020 Feb
- (9) Kaliuri K. et al. The biology, function, and biomedical applications of exosomes. Science. 2020 Feb. 7;367(6478):eaau6977. doi: 10.1126/science.aau6977. PMID: 32029601.
 (10) Vantaku V. et al. Multi-omics Integration Analysis Robustly Predicts High-Grade Patient Survival and
- Identifies CPT1B Effect on Fatty Acid Metabolism in Bladder Cancer. Clin Cancer Res. 2019 Jun 15:25(12):3689-3701. doi:10.1158/1078-0432.CCR-18-1515. PMID: 30846479.
- $\begin{tabular}{l} \textbf{(11)} Z uiverloon TC. et al. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Clin Cancer Res. 2010 Jun 1;16(11):3011-8. doi: 10.1158/1078-0432.CCR-09-3013. PMID: 20404005. \end{tabular}$
- (12) Wang J. et al. Circulating IncRNAs as noninvasive biomarkers in bladder cancer: A diagnostic metaanalysis based on 15 published articles. Int J Biol Markers. 2020 Jun;35(2):40-48. doi: 10.1177/1724600820926685. PMID:32460591.
- (13) Ebbing J. et al. Urinary calprotectin: a new diagnostic marker in urothelial carcinoma of the bladder. World J Urol. 2014 Dec;32(6):1485-92. doi: 10.1007/s00345-013-1227-8. PMID: 24378824.

 (14) Lindén M. et al. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder
- (14) Lindén M. et al. Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladde cancer. Proteomics. 2012 Jan;12(1):135-44. doi: 10.1002/pmic.201000810. PMID: 22065568.
- (15) Bhagirath D. et al. Expression of CD147, BIGH3 and Stathmin and their potential role as diagnostic marker in patients with urothelial carcinoma of the bladder. Clin Chim Acta. 2012 Oct 9;413(19-20):1641-6. doi:10.1016/j.cca.2012.05.005. PMID: 22626996.

 (16) Orenes-Piñero E. et al. Searching urinary tumor markers for bladder cancer using a two-dimensional
- (16) Orenes-Piñero E. et al. Searching urinary tumor markers for bladder cancer using a two-dimensional differential gel electrophoresis (2D-DIGE) approach. J Proteome Res. 2007 Nov;6(11):4440-8. doi: 10.1021/pr070368w. PMID:17902641.
- (18) Wittmann BM. et al. Bladder cancer biomarker discovery using global metabolomic profiling of urine. PLoS One. 2014 Dec 26;9(12):e115870. doi: 10.1371/journal.pone.0115870. PMID: 25541698.